Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLX-ADC1
- Development stage
- Preclinical
- Lead developer
- VALANX Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VLX-ADC1 is an antibody-drug conjugate (ADC) being developed by VALANX using its proprietary GoldenSite™ technology platform. The drug is designed to target LIK-1, a specific cell-surface protein, to deliver a cytotoxic payload directly to target-expressing cells. By utilizing the GoldenSite™ platform, VALANX aims to create next-generation protein-drug conjugates with precise site-specific conjugation, potentially improving the therapeutic index and stability of the ADC. It is currently in the early screening and preclinical stage of development.
02
Targets
SLC39A6 (Solute carrier family 39 member 6)
Beyond the preview
Go deeper on VLX-ADC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLX-ADC1.